3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Status
Recruiting
1
Active not recruiting
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Breast
2
Conditions
Ovarian Neoplasms
100
Breast Neoplasms
74
Fallopian Tube Neoplasms
47
Multiple Myeloma
32
Carcinoma, Ovarian Epithelial
27
Neoplasms
23
Lymphoma
15
Triple Negative Breast Neoplasms
12
Sarcoma
12
Recurrence
12
Neoplasm Metastasis
12
Lymphoma, Large B-Cell, Diffuse
10
Lymphoma, Non-Hodgkin
8
Hodgkin Disease
8
Neoplasms, Plasma Cell
6
Prostatic Neoplasms
5
Burkitt Lymphoma
5
Solid Tumors
4
Sarcoma, Kaposi
4
Sarcoma, Ewing
4
Pancreatic Neoplasms
4
Lymphoma, T-Cell, Peripheral
4
Lymphoma, Mantle-Cell
4
Leiomyosarcoma
4
Endometrial Neoplasms
4
Carcinoma
4
Breast Neoplasms, Male
4
Uterine Cervical Neoplasms
3
Rhabdomyosarcoma
3
Peritoneal Neoplasms
3
Interventions
pembrolizumab
188
Cisplatin
47
Paclitaxel
45
Carboplatin
44
lenvatinib
31
Docetaxel
23
Pemetrexed
21
Fluorouracil
20
Capecitabine
17
Gemcitabine
15
Oxaliplatin
14
Saline Solution
13
Albumin-Bound Paclitaxel
11
130-nm albumin-bound paclitaxel
10
epacadostat
9
Leucovorin
9
Cetuximab
9
olaparib
7
Irinotecan
7
Bevacizumab
7
Etoposide
6
enzalutamide
5
belzutifan
5
Dexamethasone
5
durvalumab
4
Surgical Procedures, Operative
4
Radiotherapy
4
Nivolumab
4
trifluridine tipiracil drug combination
3
spartalizumab
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Interventional
×
Parkinson Disease 4, Autosomal Dominant Lewy Body
×
liposomal doxorubicin
×
Clear all
NCT06312176
2026-05-22
MK-2870-010
Merck Sharp & Dohme LLC
Phase 3
Recruiting
1,200 enrolled
NCT04895358
2026-03-11
KEYNOTE-B49
Merck Sharp & Dohme LLC
Phase 3
Active not recruiting
340 enrolled